What is CND Life Sciences?
CND Life Sciences operates at the intersection of biotechnology and clinical diagnostics, providing essential biomarker services that address the complexities of neurodegenerative and peripheral nervous system disorders. The company distinguishes itself through the utilization of minimally invasive skin biopsies, a methodology that offers a less burdensome alternative to traditional diagnostic procedures. By integrating advanced pathological analysis, CND Life Sciences delivers objective, data-backed insights that are critical for both clinical research and patient care management. Their market position is defined by a commitment to precision medicine, enabling healthcare providers to make more informed decisions regarding the treatment of complex neurological conditions.
How much funding has CND Life Sciences raised?
CND Life Sciences has raised a total of $30.3M across 3 funding rounds:
Angel/Seed
$12.5M
Series A
$13.5M
Debt
$4.3M
Angel/Seed (2023): $12.5M, investors not publicly disclosed
Series A (2025): $13.5M led by Tanis Ventures, Cambrian Capital Partners, and BlueStone Ventures
Debt (2026): $4.3M, investors not publicly disclosed
Key Investors in CND Life Sciences
Tanis Ventures
Tanis Ventures is a firm focused on identifying and supporting high-potential innovation, currently preparing to launch new service offerings to address evolving market needs.
Cambrian Capital Partners
Cambrian Capital Partners specializes in off-market investment solutions and data-driven growth strategies, providing project financing and deal advisory services to private capital sectors.
BlueStone Ventures
BlueStone Ventures is a development-focused firm with a strong background in project management and construction, emphasizing craftsmanship and long-term client relationship building.
What's next for CND Life Sciences?
With the successful acquisition of $0, CND Life Sciences is poised to enter a phase of aggressive operational scaling and technological refinement. The company's strategic roadmap likely involves the expansion of its laboratory infrastructure to accommodate increased testing volumes and the potential integration of new diagnostic markers into its existing service portfolio. Furthermore, the infusion of capital will likely support the strengthening of partnerships with pharmaceutical entities and research institutions, thereby solidifying the company's role as a key player in the neurodiagnostic ecosystem. As the firm continues to mature, the focus will remain on enhancing the clinical utility of its biomarker platform and driving long-term value for stakeholders through sustained innovation in the life sciences sector.
See full CND Life Sciences company page
